Suppr超能文献

用于临床应用的扩增脐血来源多能间充质基质细胞的人源化系统。

Humanized system to propagate cord blood-derived multipotent mesenchymal stromal cells for clinical application.

作者信息

Reinisch Andreas, Bartmann Christina, Rohde Eva, Schallmoser Katharina, Bjelic-Radisic Vesna, Lanzer Gerhard, Linkesch Werner, Strunk Dirk

机构信息

Medical University, Department of Internal Medicine, Division of Hematology and Stem Cell Transplantation, Auenbrugger Pl. 38, A-8036, Graz, Austria.

出版信息

Regen Med. 2007 Jul;2(4):371-82. doi: 10.2217/17460751.2.4.371.

Abstract

BACKGROUND

Umbilical cord blood (UCB) is an easily accessible alternative source for multipotent mesenchymal stromal cells (MSCs) and is generally believed to provide MSCs with a higher proliferative potential compared with adult bone marrow. Limitations in cell number and strict dependence of expansion procedures from selected lots of fetal bovine serum have hampered the progress of clinical applications with UCB-derived MSCs.

METHODS

We analyzed the isolation and proliferative potential of human UCB MSCs compared with bone marrow MSCs under optimized ex vivo culture conditions. We further investigated human platelet lysate as an alternative to replace fetal bovine serum for clinical-scale MSC expansion. Clonogenicity was determined in colony-forming units-fibroblast assays. MSC functions were tested in hematopoiesis support, vascular-like network formation and immune modulation potency assays.

RESULTS

MSCs could be propagated from UCB with and without fetal bovine serum. MSC propagation was effective in 46% of UCB samples. Once established, the proliferation kinetics of UCB MSCs did not differ significantly from that of bone marrow MSCs under optimized culture conditions, resulting in more than 50 population doublings after 15 weeks. A clinical quantity of 100 million MSCs with retained differentiation potential could be obtained from UCB MSCs within approximately 7 weeks. Ex vivo expansion of hematopoietic UCB-derived CD34+ cells as well as immune inhibition and vascular-like network formation could be shown for UCB MSCs propagated under both culture conditions.

CONCLUSION

We demonstrate for the first time that human MSCs can be obtained and propagated to a clinical quantity from UCB in a completely bovine serum-free system. Surprisingly, our data argue against a generally superior proliferative potential of UCB MSCs. Functional data indicate the applicability of clinical-grade UCB MSCs propagated with human platelet lysate-conditioned medium for hematopoiesis support, immune regulation and vascular regeneration.

摘要

背景

脐带血(UCB)是多能间充质基质细胞(MSC)的一个易于获取的替代来源,并且人们普遍认为与成人骨髓相比,脐带血能为MSC提供更高的增殖潜力。细胞数量的限制以及扩增程序对特定批次胎牛血清的严格依赖阻碍了脐带血来源的MSC临床应用的进展。

方法

我们在优化的体外培养条件下,分析了人脐带血MSC与骨髓MSC的分离及增殖潜力。我们进一步研究了人血小板裂解物作为替代胎牛血清用于临床规模MSC扩增的可能性。在集落形成单位 - 成纤维细胞试验中测定克隆形成能力。在造血支持、血管样网络形成和免疫调节能力试验中测试MSC的功能。

结果

无论有无胎牛血清,MSC都可以从脐带血中扩增。46%的脐带血样本中MSC扩增有效。一旦建立,在优化培养条件下,脐带血MSC的增殖动力学与骨髓MSC没有显著差异,15周后可实现超过50次群体倍增。在大约7周内,可从脐带血MSC中获得临床所需数量的1亿个具有保留分化潜能的MSC。在两种培养条件下扩增的脐带血MSC都显示出体外扩增造血来源的CD34 +细胞以及免疫抑制和血管样网络形成的能力。

结论

我们首次证明,在完全无牛血清的系统中,可以从脐带血中获得人MSC并扩增到临床所需数量。令人惊讶的是,我们的数据表明脐带血MSC的增殖潜力并非普遍更优。功能数据表明,用人血小板裂解物条件培养基扩增的临床级脐带血MSC可用于造血支持、免疫调节和血管再生。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验